Health Condition 1: J189- Pneumonia, unspecified organism
Conditions
Interventions
Control Intervention1: nil: nil
Sponsors
Dr Avinash Agrawal
Dr Krishna Priya Agrawal
Eligibility
Inclusion criteria
Inclusion criteria: patients having clinically defined VAP according to CDC Age more than or equal to 18 years
Exclusion criteria
Exclusion criteria: Patients with evidence of chest infection prior to intubation or within 48 hours of mechanical ventilation Patients with severely immunocompromised state such as Acquired Immune Deficiency Syndrome organ transplant patients terminal stage of malignancy Patients whose sample could not be obtained Patients who are not willing to participate or give consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To study the outcome 28 days mortality of early molecular identification of Gram negative organisms causing VAP and identification of common carbapenem resistant genes KPC IMP VIM NDM or OXA 48 compared with traditional culture methodsTimepoint: At baseline 4 weeks and 90 days | — |
Secondary
| Measure | Time frame |
|---|---|
| To compare the change in targeted antibiotic therapy selection according to molecular method and culture methodTimepoint: 2 days;To compare the change in Clinical Pulmonary Infection Score on third day of management on the basis of molecular method and culture methodTimepoint: 3 days;To compare the effect of diagnosis and management of VAP by both the methods on 90 days mortalityTimepoint: 90 days | — |
Countries
India
Contacts
Public ContactProf Avinash Agrawal
King Georges Medical University Lucknow
Outcome results
None listed